Adelusi et al. [188] only covered the implications and the therapeutic potential of KEAP1/NRF2/ARE in DKD, while Sakashita [12] described briefly, in addition to the mechanism, OS as a therapeutic target, with a focus only on Bardoxolone Methyl. Here, KEAP1 is linked to diabetic kidney disease.